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PERSISTING ALVEOLITIS IN MILIARY TUBERCULOSIS
DESPITE TREATMENT WITH SHORT-COURSE
CHEMOTHERAPY
V.K. Vijayan, M.S. Jawahar, A.M. Reetha and R Prabhakar
Cardio-Pulmonary Medicine Unit, Tuberculosis Research Centre, (ICMR), Madras
Bronchoalveolar lavages in two patients with miliary tuberculosis have
shown lymphocytic alveolitis. A 6-month regimen with an initial intensive 2-
month phase resulted in remarkable clinical and radiographic improvement
in both. However, bronchoalveolar lavage following treatment has shown
that there was a persistence of lymphocytic alveolitis, though with reduced
intensity. The significance of the persisting alveolitis, despite treatment, is
not known at present. There is also a suggestion that compartment-alisation
of lymphocytes may occur in miliary tuberculosis of the lung.
Miliary disease of the lung due to Mycobacterium tuberculosis poses diagnostic as well as
therapeutic problems because of the radiographic similarity with diffuse lung diseases and
also due to the seriousness of the disease. Miliary tuberculosis is essentially an interstitial
lung disease and studies have reported lymphocytic alveolitis1 at the diagnostic stage in
these patients. Availability of potent chemotherapeutic agents2 has made it possible to treat
this condition successfully. Bronchoalveolar lavage (BAL) studies were carried out in 2
patients with radiological and bacteriological evidence of miliary tuberculosis, in order to
study the response of the alveolitis to treatment with intensive short course chemotherapy.
Case Reports
Case 1. A 24-year-old female patient complained of dyspnoea, cough, chest pain and fever
of one week duration. She was a housewife, denied any previous illness or history of
tuberculosis in the family, and was a non-smoker. On physical examination, she had
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Table. BAL in miliary tuberculosis
Pretreatment Post-treatment (6 months)
Total cells  M  L  N  E
(x106/100ml) % % % %
Total cells M L
Case 1 51.3 17 82 0 1 22.8 62 37 1 0
Case 2 48.9 25 75 0 0 21.8 25   66        6   3
M = Macrophages; L = Lymphocytes; N = Neutrophils; E = Eosinophils
dyspnoea at rest, respiratory rate was 40/min, pulse rate 144/min, temperature 99 °F and
blood pressure 100/70 mmHg. Fine rales were heard in both lung bases. Mantoux test with
1 TU PPD was 15 mm. Total leucocyte count was 11000 cells/mm3 with differentials as
polymorphs 81%, lymphocytes 17% and eosinophils 2%. There were albumin (+), 2-4 pus
cells and occasional RBCs/HPF in urine and stool did not show any ova or cyst. Skiagram
chest revealed diffuse miliary shadows in both lung fieldsespecially in the mid and lower
zones. Two sputa examined by fluorescent microscopy were negative for AFB Pulmonary
functions could not be done because of breathlessness, Blood gas studies showed a pH
7.53, PaO2 42.4 mmHg, PaCO2 25.1 mmHg and HCO3 +20.9 mmol/l. Bronchoalveolar
lavage3 using flexible fibreoptic bronchoscope showed an increase in cellularity in the lower
respiratory tract (51.3 x 106/100 ml of the lavage fluid), with 82% lymphocytes, confirming
the presence of lymphocytic alveolitis. The patient was provisionally diagnosed to be
suffering from miliary tuberculosis based on clinical, radiological and lavage findings.
She was prescribed injection streptomycin 0.75 g, isoniazid 300 mg, rifampicin 450 mg,
pyrazinamide 1 g and ethambutol 600 mg daily for the first 2 months, followed by
rifampicin 450 mg and isoniazid 300 mg daily for the next 4 months. Meanwhile, the
sputum, urine and lavage culture results were reported as positive for M. tuberculosis pre-
treatment and the organisms were sensitive to streptomycin, isoniazid, rifampicin and
ethambutol. Sputa became negative for M. tuberculosis by culture at 1st month of
treatment. During the entire period of her 6 months chemotherapy, she had missed
treatment only for a total of 16 days and she continues to be negative for M. tuberculosis by
culture in sputum at the end of 6 and 12 months. She had also shown remarkable clinical
and radiological improvement following the treatment. Pulmonary function tests at the end
of treatment revealed a mild restrictive ventilatory defect (TLC% predicted 83%, RV%
predicted 78%, FRC% predicted 83.4%) and diffusion defect (TLCO% predicted 76%).
Arterial blood gases were normal (pH 7.4, PaO2 104.2 mmHg and PaCO2 35.2 mmHg).
There was a reduction in total cells (22.8 x 106/100 ml) and lymphocytes (37%) in BAL
fluid following treatment (Table).
Case 2. A 45-year-old female patient was evaluated for cough, dyspnoea, chest pain and
fever of 3 months duration. She was a housewife and non-smoker. She also denied any
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previous illness or family history of tuberculosis. On physical examination, pulse rate was
92/min, respiratory rate 28/min, temperature 98.2 °F and BP 90/60 mmHg. There were no
abnormal signs on auscultation. Mantoux with 1 TU PPD was 19 mm, and total leucocyte
count was 10400/mm3 with differentials as polymorphs 77%, lymphocytes 15% and
eosinophils 8%. Urine and stool examinations were within normal limits. Skiagram chest
showed miliary shadows in both lung fields. Out of a total of 6 sputa, one was positive for
AFB by fluorescent microscopy. BAL showed that the total cells were 48.9 x 106/100 ml
and lymphocytes were 75%, confirming the presence of lymphocytic alveolitis in this
patient as well. She was given injection streptomycin 0.75 g, isoniazid 400 mg, rifampicin
450 mg and pyrazinamide 1.5 g thrice weekly for the first two months followed by
streptomycin 0.75 g, isoniazid 600 mg and rifampicin 450 mg twice-weekly for the next 4
months. However, streptomycin was terminated at the end of 5th month due to giddiness.
Her pre-treatment sputa and lavage cultures became positive for M. tuberculosis and the
organisms were sensitive to streptomycin, isoniazid and rifampicin. Sputa became negative
for M. tuberculosis by culture at 1st month of treatment. She had missed only one dose
during the entire 6 months period of chemotherapy. She had also shown remarkable
clinical and radiographic improvement following treatment and sputa continued to be
negative for M. tuberculosis by culture at 6 and 12 months. BAL at 6 months had shown
that total cells were 21.8 x 106/100 ml and lymphocytes were 66% (Table). Pulmonary
function tests revealed that there was diffusion defect (TLCO% predicted 59.4%), with
normal lung volumes.
Discussion
Clinical trials in tuberculous meningitis: pulmonary tuberculosis2, spinal tuberculosis5
and tuberculosis of lymphnodes6 had shown that treatment with potent bactericidal and
sterilising drugs for 6-9 months is adequate for remarkable therapeutic response. Though
no controlled clinical trials in miliary tuberculosis of the lung have been reported, the
highly satisfactory clinical response and complete radiographic resolution of the lesions in
our patients suggest that 6 months treatment may be adequate for a bacteriological
response in these patients.
Lymphocytic alveolitis in miliary tuberculosis prior to treatment has previously been
reported1. Since the mean lymphocytes in BALF in our normal subjects3 were 21 (SE ±
4%), the patients with lymphocytes > 31% in BAL fluid was classified as having
lymphocytic alveolitis. The persistence of lymphocytic alveolitis with reduced intensity in
our patients even after treatment with potent chemotherapeutic regimen requires further
indepth study. Will the alveolitis subside spontaneously as time passes or will it produce any
deleterious effects on the lung parenchyma? Long term follow-up of such patients are
essential to answer these questions. As it has been shown that lymphocytic alveolitis can
cause lung injury and fibrosis in sarcoidosis and hypersensitivity pneumonitis7, there is a
possibility that alveolitis observed in miliary tuberculosis patients, despite treatment, may
cause injury to lung parenchyma. In addition, the finding of reduced transfer factor at 6
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month in our patients is also significant. Immunological investigations using BAL coupled
with long term clinical and pulmonary function studies are required to unravel the mystery.
If there is a possibility that these patients might develop interstitial fibrosis, the role of
steroids in the management of miliary disease of the lung due to M. tuberculosis has to be
critically evaluated, as it had been shown recently that anti-tuberculosis chemotherapy
should be initially supplemented with steroids in patients with tuberculous constrictive
pericarditis,8 if there are no contra-indications. Another interesting finding in these patients
is the occurrence of relative lymphopenia in peripheral blood, as opposed to lymphocytosis
in BAL fluid, suggesting that there may be compartmentalisation of lymphocytes in miliary
tuberculosis. An increased number of helper/inducer T-lymphocytes at sites of
involvement had been previously reported in tuberculous pleural effusion9, tuberculoid
leprosy10, pulmonary sarcoidosis11, rheumatoid arthritis12 and hypersensitivity
pneumonitis13. It had been demonstrated in tuberculous pleural effusion that pleural T-
lymphocytes, but not blood T-lymphocytes, released gamma interferon when exposed to
PPD14, suggesting that the immune response is also compartmentalised in tuberculous
pleurisy. The observation of increased lymphocytes in BAL fluid and a simultaneous
decrease in lymphocytes in periphera1 brood in our patients warrants further extensive
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